DekaBank Deutsche Girozentrale
INZY

DekaBank Deutsche Girozentrale’s Inozyme Pharma INZY Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,000
Closed -$78K – 1444
2021
Q3 		$78K Hold
7,000
– – ﹤0.01% 1315
2021
Q2 		$119K Hold
7,000
– – ﹤0.01% 1309
2021
Q1 		$128K Hold
7,000
– – ﹤0.01% 1260
2020
Q4 		$170K Buy
+7,000
New +$167K ﹤0.01% 1205

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DekaBank Deutsche Girozentrale's INZY Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Inozyme Pharma (INZY) in Q4 2021, closing a stake of 7,000 shares — an estimated $78K sold.

DekaBank Deutsche Girozentrale first reported a position in INZY in Q4 2020 and held it in 4 quarters. The position peaked at $170K in Q4 2020. 51 funds tracked by Wall St. Rank hold INZY as of Q4 2021.

  • DekaBank Deutsche Girozentrale reported no remaining Inozyme Pharma position as of Q4 2021 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 7,000 Inozyme Pharma shares in Q4 2021, an estimated $78K.
  • DekaBank Deutsche Girozentrale first reported a position in Inozyme Pharma in Q4 2020 and held it in 4 quarters.
  • DekaBank Deutsche Girozentrale's Inozyme Pharma position peaked at $170K in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.